Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr

Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr

The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025

Sanofi India posts 27% growth in operating profits in Q1 2025

Standalone profit from operations for the quarter were Rs. 162 crores

Briefs: Zydus and CuraTeQ Biologics

CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%

Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection

Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy

Wanbury's Tanuku facility granted GMP certificate by ANVISA

The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)

Borealis advancing sustainability medical devices with the Bornewables

The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices